0.80
Precedente Chiudi:
$0.8305
Aprire:
$0.82
Volume 24 ore:
233.98K
Relative Volume:
0.26
Capitalizzazione di mercato:
$15.66M
Reddito:
$1.89M
Utile/perdita netta:
$-17.92M
Rapporto P/E:
-0.1196
EPS:
-6.69
Flusso di cassa netto:
$-15.62M
1 W Prestazione:
-13.88%
1M Prestazione:
+1.48%
6M Prestazione:
-48.72%
1 anno Prestazione:
-62.96%
Longeveron Inc Stock (LGVN) Company Profile
Nome
Longeveron Inc
Settore
Industria
Telefono
305-302-7158
Indirizzo
1951 NW 7TH AVENUE, MIAMI
Confronta LGVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
LGVN
Longeveron Inc
|
0.80 | 17.49M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
Longeveron Inc Borsa (LGVN) Ultime notizie
Why analysts upgrade Longeveron Inc. stockRisk Management & Real-Time Market Trend Scan - newser.com
Is Longeveron Inc. stock in correction or buying zoneJuly 2025 Earnings & Reliable Volume Spike Alerts - newser.com
Earnings To Watch: Longeveron Inc (LGVN) Reports Q3 2025 Result - GuruFocus
Is it too late to sell Longeveron Inc.July 2025 Outlook & Daily Growth Stock Investment Tips - newser.com
Will Longeveron Inc. stock remain a Wall Street favoriteWeekly Stock Summary & Consistent Income Trade Recommendations - newser.com
What dividend safety score for Longeveron Inc. stockJuly 2025 News Drivers & AI Forecast Swing Trade Picks - newser.com
Visualizing Longeveron Inc. stock with heatmapsQuarterly Profit Report & Capital Efficiency Focused Strategies - newser.com
What data driven models say about Longeveron Inc.’s futureWeekly Investment Summary & Low Volatility Stock Recommendations - newser.com
Can you recover from losses in Longeveron Inc.July 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com
How to recover losses in Longeveron Inc. stockCEO Change & Long-Term Capital Growth Strategies - newser.com
What analysts say about Longeveron Inc stockBullish Engulfing Patterns & Free Dashboard to Track Market Momentum - earlytimes.in
Will Longeveron Inc. stock continue dividend increasesWeekly Trade Analysis & Low Drawdown Momentum Ideas - newser.com
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 - The Manila Times
Should you wait for a breakout in Longeveron Inc.Market Rally & Smart Investment Allocation Tips - newser.com
Will Longeveron Inc. stock deliver strong dividend growth2025 Breakouts & Breakdowns & Consistent Growth Equity Picks - Fundação Cultural do Pará
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect - The Manila Times
Longeveron (NASDAQ: LGVN) completes ELPIS II enrollment; HLHS trial top-line Q3 2026 - Stock Titan
Longeveron Inc Azioni (LGVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Longeveron Inc Azioni (LGVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):